Skip to main content

Table 2 Associations between liver enzyme elevation and various demographic and clinical variables

From: A prospective study of hepatic safety of statins used in very elderly patients

CharacteristicsPresence of liver enzyme elevationP valueOdds ratio (95% CI)
YesNo
(n = 24, 4.7%)(n = 491, 95.3%)
Age (years)82.6 ± 3.8a83.9 ± 3.4a  
 80  8519(3.7%)b308(59.8%) 1.000
 85  903(0.6%)149(28.9%)0.0750.326(0.095, 1.120)
  ≥ 902(0.4%)34(6.6%)0.9500.954(0.213, 4.271)
Sex
 Male20(3.9%)390(75.7%) 1.000
 Female4(0.8%)101(19.6%)0.6440.772(0.258, 2.310)
Hepatitis B
 No16(3.1%)477(92.6%) 1.000
 Yes8(1.6%)14(2.7%)< 0.00117.036(6.259, 46.371)
Fatty liver
 No16(3.1%)450(87.4%) 1.000
 Yes8(1.6%)41(8.0%)0.0093.659(1.376, 9.726)
Biliary calculus
 No16(3.1%)411(79.8%) 1.000
 Yes8(1.6%)80(15.5%)0.0362.570(1.064, 6.206)
Other diseases
  ≤ 21(0.2%)30(5.8%) 1.000
 3  59(1.7%)203(39.4%)0.7901.330(0.163, 10.875)
  ≥ 514(2.7%)258(50.1%)0.6441.628(0.207, 12.820)
Other drugs
  < 55(1.0%)94(18.3%) 1.000
 5  1016(3.1%)352(68.3%)0.7650.855(0.305, 2.393)
  ≥ 103(0.6%)45(8.7%)0.7641.253(0.287, 5.477)
Drinking habits
 No drinking8(1.6%)483(93.8%) 1.000
 Mild to moderate11(2.1%)3(0.6%)0.4251.585(0.511, 4.914)
 Heavy5(1.0%)5(1.0%)< 0.00127.733(7.245,106.164)
Statin variety
 Simvastatin6(1.2%)92(17.5%) 1.000
 Fluvastatin8(1.6%)108(21.0%)0.8201.136(0.380, 3.393)
 Pravastatin4(0.8%)76(14.8%)0.7470.807(0.220, 2.964)
 Rosuvastatin1(0.2%)84(16.3%)0.1190.183(0.022, 1.548)
 Atorvastatin5(1.0%)131(25.4%)0.3880.585(0.173, 1.975)
Statin dose
 Low4(0.8%)66(12.8%) 1.000
 Standard20(3.9%)425(82.5%)0.6530.776(0.257, 2.342)
  1. adata are expressed as mean ± SD. ball percentages in the table are of the total samples (n = 515)